Return to the full list of Biomarkers
[18F]T807 PET (TEPTAU)
Method of Measurement (Pre-analytical Tools)
Imaging
Biomarker Measured
Tau
Use
Prognostic
Stage of Development
Clinical trials
Active vs Completed Trials
Active
Aim/Results
To examine if there is a different regional pattern of tracer retention across brain regions according to clinical symptoms : temporal for logopenic aphasia and occipital for posterior cortical atrophy.
Target Population/ Population Being Studied
Patients with AD, patients with Benson disease, and healthy volunteers
Length of Current Trial
3 months
Number of Trial Participants
17
Estimated Trial Completion
August 2019
What is Required from Patients
injection of radioactive tracers, mild discomfort, in clinic visit
What is Required from the Health System
PET technician, PET scanner, dyes
Sponsor
University Hospital, Tours
“Tau Brain Imaging in Typical and Atypical Alzheimer's Disease (AD) (TEPTAU).”ClinicalTrials.gov. Accessed October 9, 2019. https://clinicaltrials.gov/ct2/show/NCT03022968?term=biomarker&recrs=abdf&cond=Alzheimer+Disease&draw=6&rank=54